Ammunition Raises ￥10M in Series A Financing, Focusing on Early Detection of Cancer

According to VCBeat, Wuhan Ammunition Life Technology Co., Ltd. ("Ammunition") announced the completion of its Series A financing of tens of millions yuan, with participation from CCBI Health Care Growth Fund Proceeds from this round will be used to accelerate the development and marketing of the company's early detection products of cancer.

Founded in 2015, Ammunition is committed to building the world's leading platform for tumor screening, providing early detection products and services, to fundamentally reducing the incidence and mortality of tumors and medical costs. Previously, Ammunition has obtained the investment from Guangdong Hybribio Biotech, the domestic leading enterprise in cervical cancer screening and detection.

As a company targeting cancer screening, Ammunition focuses on the development of early detection products based on clinical big data, bioinformatics, epigenetics, new biological materials, and other technologies.

Ammunition always takes "Early, Accurate, Non-invasive and Convenient" as the product concept. At present, the company has completed the development of early detection products for colorectal cancer, cervical cancer, esophageal cancer, endometrial cancer, and others. At the same time, Ammunition expands to the pan-cancer cancer detection field through the layout of other cancer screening products. "That's the main reason why the capital chooses us", said Zhang Lianglu, the founder of Ammunition.

Ammunition's flagship product AiChangKang^® is a colorectal cancer screening product based on fecal DNA. It was developed according to the intestinal characteristics of Chinese, which has good complementarity of double targets detection, combining the sensitivity of left colorectal cancer detection with the right, thus greatly improving the accuracy of the result.

The detection sensitivity of AiChangKang^® for colorectal cancer and adenoma (pre-cancerous lesions) is better than that of similar products in the market. This product can be compared with Cologuard, the product of the American company, Exact Sciences, which has the efficacy ratio 10 times more than that of Cologuard.

CCBI Health Care Growth Fund was initiated and established by CCB International (CCBI), with the first-phase scale of 500 million yuan. This fund is focused on the investment of healthcare startups in the early and growth stage.